Dr. Lindsey Rolfe
BSc, MB ChB, MRCP, FFPM
Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance and Chief Medical Officer
Dr. Lindsey Rolfe has served as our Executive Vice President of Clinical and Pre-Clinical Development and
Pharmacovigilance and Chief Medical Officer since August 2015. Dr. Rolfe joined Clovis in April 2010 and
served as Senior Vice President of Clinical Development until her promotion. Dr. Rolfe has 20 years of drug
development experience and previously served in senior oncology development roles at Celgene Corporation,
Pharmion Corporation (acquired in 2008), Cambridge Antibody Technology, UCB Inc. and Celltech Group plc.
Dr. Rolfe also serves on the board of directors of Atreca, Inc. (NASDAQ: BCEL). Dr. Rolfe qualified in
medicine at the University of Edinburgh. She undertook post graduate medical training in London, U.K. and
obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians
(MRCP). She has specialist accreditation in Pharmaceutical Medicine from the U.K. General Medical Council
and is a Fellow of the Faculty of Pharmaceutical Medicine.